
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen Preparations are underway for FDA interactions and initiation of …